Development of rheumatoid arthritis during the course of gefitinib therapy.
Ohara
Gen
G
Satoh
Hiroaki
H
Kohno
Mika
M
Goto
Daisuke
D
Sumida
Takayuki
T
Hizawa
Nobuyuki
N
D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000209:etiology*; D004347:Drug Interactions; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D011239:Prednisolone / Q000008:administration & dosage; D011799:Quinazolines / Q000009:adverse effects*; D012460:Sulfasalazine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D018501:Antirheumatic Agents; D011799:Quinazolines; D012460:Sulfasalazine; D011239:Prednisolone; D000077156:Gefitinib